35 patents
Page 2 of 2
Utility
Integral membrane protein display on poxvirus extracellular enveloped virions
21 Dec 20
This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
Filed: 25 Dec 19
Utility
Polynucleotides encoding anti-CXCL13 antibodies
9 Nov 20
Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers.
Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
Filed: 12 Apr 18
Utility
Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
12 Oct 20
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
Filed: 1 Jul 19
Utility
SEMAPHORIN-4D Antagonists for Use In Cancer Therapy
7 Oct 20
The disclosure relates to methods for treating cancer comprising determining certain patient biomarker levels prior to treatment.
Terrence Lee Fisher, Elizabeth Evans, Maurice Zauderer
Filed: 26 Mar 20
Utility
Methods for Producing Polynucleotide Libraries In Vaccinia Virus/eukaryotic Cells
23 Sep 20
This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest.
Ernest SMITH, Shuying SHI
Filed: 27 Apr 20
Utility
Integral Membrane Protien Display on Poxvirus Extracellular Enveloped Virions
8 Jul 20
This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
Ernest S. Smith, Mark Paris, Maria G.M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
Filed: 25 Dec 19
Utility
Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
25 May 20
The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells.
Ernest S. Smith, Tracy Pandina, Leslie A. Balch, Mark Paris, Maurice Zauderer, Angelica Cornelison, Renee Kirk
Filed: 11 Jun 17
Utility
Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
4 May 20
This disclosure provides an improved method of constructing a library of polynucleotides of interest in a poxvirus, e.g., vaccinia virus vector system, where the polynucleotides of interest encode polypeptides of interest.
Ernest Smith, Shuying Shi
Filed: 14 Apr 19
Utility
Integral membrane protein display on poxvirus extracellular enveloped virions
2 Mar 20
This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
Filed: 20 Apr 17
Utility
Integral membrane protein display on poxvirus extracellular enveloped virions
3 Feb 20
This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
Filed: 14 Apr 19
Utility
Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases
6 Jan 20
Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
Filed: 31 Jul 17
Utility
Early Detection of Glial Cell Activation In Neurodegenerative or Neuroinflammatory Diseases
18 Dec 19
The disclosure provides a method for determining the efficacy of treatment with a SEMA4D antagonist, e.g., a SEMA4D antagonist antibody in the treatment of a neuroinflammatory or neurodegenerative disease, disorder, or injury, where the method provides differential measurement of glucose uptake in the brain, e.g., by FDG-PET imaging.
Maurice ZAUDERER
Filed: 19 Feb 18
Utility
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
2 Dec 19
Provided herein are methods for promoting neurogenesis in neural tissue of a patient exhibiting at least one symptom of a central nervous system disorder, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
Ernest S. Smith, Maurice Zauderer
Filed: 14 Mar 13
Utility
Use of SEMAPHORIN-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
27 Nov 19
Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
Ernest S. Smith, Maurice Zauderer
Filed: 5 Jun 19
Utility
Use of SEMAPHORIN-4D Binding Molecules for Treating Neurodegenerative Disorders
23 Oct 19
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
Filed: 1 Jul 19